Dr. Roy Choudhury’s research focuses on investigating the epigenetic regulatory mechanisms at the enhancers and promoters of the critical oncogenes and tumor suppressors that drive malignant proliferation and invasion during leukemogenesis in the Acute Myeloid Leukemia (AML) patients, characterized with BET (BRD4), SET (KMT2A, EZH2, and NSD1) or runt (CBFA2T3) over-expressed domains. His laboratory uses the multi-omics platform to identify the alterations in DNA methylation, histone modifications and transcription factor assemblies in and outside the topologically assorted domains (TAD) in AML. His work also aims to study the recurrent epigenetic mutations in AML patients in relation to their effect on the cancer cell metabolism.